文摘
Treatment-induced ovarian function loss is of great concern for young breast cancer patients. The protective role of luteinising hormone-releasing hormone analogues (LHRHa) during chemotherapy has been highly debated in the last years. Grades of Recommendation, Assessment, Development and Evaluation approach by the Italian Association of Medical Oncology (AIOM) to investigate this issue. The Panel of the AIOM Clinical Practice Guideline recommends the use of LHRHa during chemotherapy.